National Peroxide Ltd Valuation Shifts to Attractive Amid Strong Market Returns

Valuation Metrics and Market Context

As of 18 May 2026, National Peroxide’s stock closed at ₹642.80, down 1.20% from the previous close of ₹650.60. The stock’s 52-week trading range spans from ₹350.00 to ₹770.00, indicating significant volatility over the past year. The company’s current P/E ratio stands at 31.55, a figure that has contributed to its reclassification from a very attractive valuation grade to an attractive one. This shift is notable given the company’s micro-cap status and the broader commodity chemicals industry dynamics.

In comparison to its peers, National Peroxide’s valuation remains moderate. For instance, Titan Biotech and Sanstar are classified as very expensive with P/E ratios of 68.8 and 94.16 respectively, while Stallion India is expensive at 37.39. On the other hand, Gulshan Polyols and TGV Sraac are considered very attractive with P/E ratios of 28.08 and 9.36 respectively. This places National Peroxide in a middle ground, reflecting a balance between growth expectations and risk.

Price-to-Book Value and Enterprise Value Multiples

The company’s price-to-book value ratio is currently 1.01, signalling that the stock is trading close to its book value. This is a critical indicator for investors assessing the tangible asset backing of the company. Additionally, the enterprise value to EBITDA (EV/EBITDA) ratio is 9.85, which is relatively reasonable within the commodity chemicals sector, where peers like Sanstar exhibit much higher multiples (96.29) and others like TGV Sraac show lower multiples (4.24).

Enterprise value to EBIT (EV/EBIT) stands at 29.54, while EV to capital employed and EV to sales are 1.02 and 1.06 respectively. These ratios suggest that while the company is not undervalued, it maintains a valuation that is attractive relative to its earnings and capital base, especially when compared to more expensive peers.

Profitability and Growth Indicators

National Peroxide’s return on capital employed (ROCE) and return on equity (ROE) are modest at 3.44% and 3.21% respectively. These figures indicate limited profitability relative to the capital invested and shareholder equity, which may partly explain the tempered valuation despite the company’s growth prospects.

The PEG ratio, an important metric that adjusts the P/E ratio for earnings growth, is exceptionally low at 0.05. This suggests that the stock’s price is low relative to its expected earnings growth, a positive sign for value-oriented investors. However, the low ROCE and ROE temper enthusiasm, signalling that earnings quality and capital efficiency remain areas for improvement.

Stock Performance Relative to Sensex

Examining the stock’s recent performance relative to the benchmark Sensex index reveals a strong outperformance over multiple time horizons. Over the past month, National Peroxide’s stock surged 56.1%, while the Sensex declined 3.68%. Year-to-date, the stock has gained 37.35%, contrasting with an 11.71% decline in the Sensex. Even over the past year, the stock posted a 7.58% gain against an 8.84% loss for the benchmark.

This relative strength underscores the company’s resilience and investor interest despite the recent slight price pullback. The stock’s ability to outperform the broader market is a key factor supporting its attractive valuation grade.

Peer Comparison and Industry Positioning

Within the commodity chemicals sector, National Peroxide’s valuation and financial metrics position it as an attractive option for investors seeking exposure to this space without the premium valuations seen in some peers. While companies like Titan Biotech and Sanstar command very high multiples, National Peroxide’s more moderate valuation offers a compelling risk-reward balance.

However, the company’s micro-cap status and modest profitability metrics suggest that investors should weigh growth potential against operational risks. The sector itself is subject to cyclical demand and raw material price volatility, factors that could influence future earnings and valuation.

Outlook and Investment Considerations

National Peroxide’s recent downgrade in mojo grade from Buy to Hold on 13 May 2026 reflects a cautious stance amid shifting valuation parameters. The company’s mojo score of 62.0 supports this Hold rating, indicating moderate confidence in its near-term prospects.

Investors should consider the company’s valuation in the context of its growth trajectory, profitability metrics, and sector dynamics. While the stock’s P/E and P/BV ratios remain attractive relative to many peers, the modest returns on capital and equity highlight the need for operational improvements to sustain valuation support.

Given the stock’s strong recent price performance relative to the Sensex, there may be opportunities for gains, but the risk of valuation compression remains if earnings do not improve or if sector headwinds intensify.

Overall, National Peroxide Ltd presents a balanced investment case with valuation attractiveness tempered by profitability challenges and market volatility. Investors seeking exposure to commodity chemicals with a micro-cap tilt may find this stock worthy of consideration within a diversified portfolio.

Summary of Key Financial Metrics

• Current Price: ₹642.80
• P/E Ratio: 31.55 (Attractive valuation grade)
• Price to Book Value: 1.01
• EV/EBITDA: 9.85
• ROCE: 3.44%
• ROE: 3.21%
• PEG Ratio: 0.05
• Mojo Score: 62.0 (Hold rating)
• Market Cap Grade: Micro-cap

Investors should monitor upcoming quarterly results and sector developments to reassess valuation and growth prospects.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →